All enrolled patients who obtained a minimum of 1 dose of zosuquidar or placebo for the duration of induction have been monitored to the event of adverse functions (439 sufferers, 219 on zosuquidar and 210 on placebo). The most common adverse events were being relevant to the period of prolonged https://donovanfasix.spintheblog.com/28416029/a-secret-weapon-for-ly-3000328